NCT06386744Phase 2Completed

Dusquetide for the Treatment of Behcet's Disease

Study sponsor: Soligenix

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-05-23Actual

Enrollment · participants8Actual

Source updated2026-08-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Behçet Disease

Treatments or interventions studied

DusquetideDrugAlso known as SGX945, SGX942

Primary outcomes · main study measures

measure: Number of Oral Ulcers; description: The number of oral ulcers were counted at baseline and each visit during the treatment period.; timeFrame: 4 weeks; measure: Number of Genital Ulcers; description: The number of genital ulcers will be counted at baseline and each visit during the treatment period.; timeFrame: 4 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history